In agreement with this, it has been shown that in ATRA-sensitive pancreatic cancer cell lines, increased expression of CRABP2 as well as the tumor suppressors charged multivesicular body protein 1A (Chmp1A) and p53 occurs after ATRA treatment, whereas Chmp1A knockdown abrogates ATRA-mediated growth inhibition [71]. The gene discussed is TP53; the disease is pancreatic neoplasm.